Seres Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Seres Therapeutics, Inc. (MCRB) had Debt Securities, Available-for-sale, Amortized Cost of $11.70 million as of 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2024-08-15
- 2023-03-31: Debt Securities, Available-for-sale, Amortized Cost $11.70M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $18.32M.
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost $27.72M.
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost $69.23M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2023-03-31 | $11.70M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $18.32M 8-K · filed 2024-08-15 |
| 2022-09-30 | $27.72M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $69.23M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $95.02M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $111.26M 10-K · filed 2023-03-07 |
| 2021-09-30 | $125.70M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $155.42M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $205.99M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $187.44M 10-K · filed 2022-03-01 |
| 2020-09-30 | $112.98M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $2.40M 10-Q · filed 2020-07-28 |
| 2020-03-31 | $20.25M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $29.69M 10-K · filed 2021-03-02 |
| 2019-09-30 | $34.48M 10-Q · filed 2019-11-05 |
| 2018-09-30 | $17.18M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $38.13M 10-Q · filed 2018-08-02 |
| 2017-12-31 | $114.04M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |